ICD-10 Coding for Prostate-Specific Antigen (PSA) Testing(N40.1U, R97.2, R97.20)
Learn about PSA ICD-10 coding, including codes for elevated PSA and screening. Ensure accurate documentation and billing with our expert guide.
Complete code families applicable to Prostate-Specific Antigen (PSA) Testing
Compare key differences between these codes to ensure accurate selection
| Code | Description | When to Use | Key Documentation |
|---|---|---|---|
| R97.20 | Elevated prostate specific antigen [PSA] | Use when PSA levels are elevated but no cancer diagnosis is confirmed. |
|
| Z12.5 | Encounter for screening for malignant neoplasm of prostate | Use for routine PSA screening in asymptomatic patients. |
|
| Z85.46 | Personal history of malignant neoplasm of prostate | Use for patients with a history of prostate cancer, especially in follow-up visits. |
|
Clinical Decision Support
Always review the patient's clinical documentation thoroughly. When in doubt, choose the more specific code and ensure documentation supports it.
Key Information
Essential facts and insights aboutProstate-Specific Antigen (PSA) Testing
Alternative codes to consider when ruling out similar conditions
Documentation & Coding Risks
Avoid these common issues when documenting Prostate-Specific Antigen (PSA) Testing.
Failing to document PSA value
Impact
Clinical: Leads to incomplete patient records., Regulatory: May result in coding errors and compliance issues., Financial: Can cause claim denials due to lack of specificity.
Mitigation
Always include PSA values in documentation, Ensure context is provided for elevated levels
Using C61 for PSA monitoring post-treatment
Impact
Reimbursement: Incorrect coding can lead to claim denials., Compliance: Using active cancer codes for history cases violates coding guidelines., Data Quality: Misrepresents patient history in medical records.
Mitigation
Use Z85.46 for history of prostate cancer instead.
Reporting G0103 with R97.20
Impact
Reimbursement: Medicare denies claims when screening codes are used with diagnostic findings., Compliance: Violates Medicare's coding rules for PSA tests., Data Quality: Leads to inaccurate data on screening vs. diagnostic tests.
Mitigation
Use 84153 for diagnostic PSA tests.
Incorrect use of screening codes
Impact
Using screening codes for diagnostic purposes can trigger audits.
Mitigation
Ensure documentation clearly differentiates between screening and diagnostic tests.